Navigation Links
Regenicin Announces Closing of Private Placement Transaction
Date:11/11/2010

NEW YORK, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced the closing of a private placement. Regencin secured proceeds of $467,550.25. In addition the company converted $500,000 of debt into equity.

The proceeds, net of placement agent fees and expenses, will be used to continue to develop its innovative regenerative medicine platform.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

The securities have not been, and will not be, registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Regenicin

Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
2. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
3. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
4. Regenicin to Form Scientific Advisory Board
5. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
6. Regenicin to Present Live at RetailInvestorConferences.com on November 4th
7. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
8. Regenicin Presentation Now Available Online at RetailInvestorConferences.com
9. Regenicin Changes Its Ticker Symbol to RGIN.OB
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... READING, England , May ... ( http://www.indegene.com ), ein führender Anbieter von ... Life-Science-Branche, Pharmaunternehmen und Gesundheitsorganisationen, und TranScrip ( ... innovativen wissenschaftlichen Support-Services für den gesamten Produktlebenszyklus, ... heute den Ausbau ihrer bestehenden Allianz an. ...
(Date:5/26/2016)... , May 26, 2016 Despite ... see value in this space. Today,s pre-market research on ActiveWallSt.com ... Radius Health Inc. (NASDAQ: RDUS ), Cerus Corp. ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... technical briefings at: http://www.activewallst.com/ ...
(Date:5/25/2016)... Thailand (PRWEB) , ... May 25, 2016 , ... ... participation of a Thai delegation at BIO 2016 in San Francisco. Located at ... sector will be available to answer questions and discuss the Thai biotechnology and ...
(Date:5/25/2016)... LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been named ... as WEDI’s interim CEO since January 2016. As an executive leader with more than ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):